BiotechTube

GEN3017

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Classical Hodgkin Lymphoma

Conditions

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma

Trial Timeline

Sep 21, 2023 → Feb 5, 2025

NCT ID
NCT06018129

About GEN3017

GEN3017 is a phase 1/2 stage product being developed by Genmab for Classical Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06018129. Target conditions include Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma.

What happened to similar drugs?

0 of 2 similar drugs in Classical Hodgkin Lymphoma were approved

Approved (0) Terminated (1) Active (1)
🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3
❌Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06018129Phase 1/2Terminated

Competing Products

11 competing products in Classical Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3
36
Sabestomig (AZD7789)AstraZenecaPhase 1
29
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotinMerckPhase 2
42
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + PrednisoneMerckPhase 2
35
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine SulfateMerckPhase 2
31
Carboplatin + Etoposide + Ifosfamide + PembrolizumabMerckPhase 2
31
Pembrolizumab (+) Berahyaluronidase alfaMerckPhase 2
39
PanobinostatNovartisPhase 2
35
PD1Innovent BiologicsPhase 2
35
Nivolumab + Autologous CD30.CAR-T + Fludarabine + BendamustineBristol Myers SquibbPhase 1
33
Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3
29